isotretinoin and Carcinogenesis

isotretinoin has been researched along with Carcinogenesis* in 2 studies

Other Studies

2 other study(ies) available for isotretinoin and Carcinogenesis

ArticleYear
Toxicity, Genotoxicity, and Carcinogenicity of Isotretinoin.
    Current molecular pharmacology, 2023, Volume: 16, Issue:1

    Acne is a chronic inflammatory disease mainly observed in adolescence, but it can also be seen during the neonatal, infantile, pre-pubertal, and adult periods. Isotretinoin (13-cis-retinoic acid) is a first-generation retinoid and is the most effective treatment for acne vulgaris.. The present study has been systematically designed to figure out the toxic, genotoxic, and carcinogenic activities of isotretinoin.. In this study, a systematic approach was followed by focusing on the possible links between these topics. The search of the databases was carried out author in accordance with the guidelines of the Centre for Reviews and Dissemination (2009) developed by York University National Institute of Health Research. The search was concentrated on the Web of Science, PubMed, Science Direct, Scopus, EBSCO Host, and Google Scholar databases.. Isotretinoin was found as a toxic agent in all studies. All researchers proposed that apoptosis is the only pathway of adverse effects of isotretinoin. However, genotoxicity, teratogenicity, and carcinogenicity information of isotretinoin is very limited and controversial.. More detailed studies need to clarify the genotoxic and carcinogenic potential of isotretinoin. Patients should be informed correctly, the risks of treatment should be explained, and awareness should be raised.

    Topics: Adolescent; Adult; Apoptosis; Carcinogenesis; DNA Damage; Humans; Infant, Newborn; Isotretinoin; Retinoids

2023
UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.
    Journal of neuro-oncology, 2018, Volume: 140, Issue:2

    Group 3 tumors account for approximately 25-30% of medulloblastomas and have the worst prognosis. UAB30 is a novel synthetic rexinoid shown to have limited toxicities in humans and significant efficacy in the pediatric neuroectodermal tumor, neuroblastoma. We hypothesized that treatment with UAB30 would decrease tumorigenicity in medulloblastoma patient-derived xenografts (PDXs).. Three group 3 medulloblastoma PDXs (D341, D384 and D425) were utilized. Cell viability, proliferation, migration and invasion assays were performed after treatment with UAB30 or 13-cis-retinoic acid (RA). Cell cycle analysis was completed using flow cytometry. A flank model, a cerebellar model, and a model of leptomeningeal metastasis using human medulloblastoma PDX cells was used to assess the in vivo effects of UAB30 and RA.. UAB30 treatment led to cell differentiation and decreased medulloblastoma PDX cell viability, proliferation, migration and invasion and G1 cell cycle arrest in all three PDXs similar to RA. UAB30 and RA treatment of mice bearing medulloblastoma PDX tumors resulted in a significant decrease in tumor growth and metastasis compared to vehicle treated animals.. UAB30 decreased viability, proliferation, and motility in group 3 medulloblastoma PDX cells and significantly decreased tumor growth in vivo in a fashion similar to RA, suggesting that further investigations into the potential therapeutic application of UAB30 for medulloblastoma are warranted.

    Topics: Animals; Antineoplastic Agents; Carcinogenesis; Cells, Cultured; Cerebellar Neoplasms; Fatty Acids, Unsaturated; Female; Humans; Isotretinoin; Medulloblastoma; Meningeal Carcinomatosis; Mice, Nude; Naphthalenes; Neoplasm Transplantation; Random Allocation; Retinoid X Receptors

2018